Core Viewpoint - The Guangzhou Baiyun District is launching a three-year action plan (2026-2028) to accelerate the high-quality development of the biomanufacturing industry, establishing a comprehensive ecosystem to enhance the sector's competitiveness and output [1][2]. Group 1: Action Plan and Ecosystem - The action plan outlines the construction of a "11221" industrial ecosystem, which includes the establishment of 1 biomanufacturing innovation center, 1 pilot base, 2 achievement transformation platforms, two phases of over 1,000 acres of biomanufacturing industrial parks, and a biomanufacturing fund cluster with a scale of 100 billion [1][2]. - The goal is to drive the output value of related biomanufacturing industries to exceed 50 billion by 2028, positioning the area as a leading biomanufacturing hub with national competitiveness [1]. Group 2: Capital and Project Collaboration - A biomanufacturing fund cluster with a total scale of 10 billion has been established, led by Baiyun Investment Group and supported by various top investment institutions and industry leaders, aiming to create a "state-owned enterprise leading + professional fund management + industry enterprise collaboration" structure [2]. - The first phase of the fund has completed a 1 billion fundraising, covering the entire lifecycle of biomanufacturing enterprises from startup to Pre-IPO [2]. Group 3: Project Signings - The event featured significant project signings in areas such as biomedicine, biomaterials, and biocosmetics, including plans for a cell culture medium and CDMO production base by Auscon Biotech, and a core component R&D and production base for mass spectrometers by Shandong Yingsheng Biotech [2]. - Blue Bay Technology will develop a biomanufacturing industrial park that integrates R&D, pilot testing, and production, providing systematic services for technology transformation and enterprise growth [2]. Group 4: Ongoing Support - Guangzhou's municipal departments will continue to support Baiyun District in leveraging its industrial foundation and innovative resources to implement biomanufacturing development policies and facilitate the transformation of more research outcomes [3].

Core Viewpoint - The article discusses the escalating conflict between two major players in the biocosmetics industry, Huaxi Biological and Juzhi Biological, triggered by a dispute over product testing results and allegations of misleading information [2][5][10]. Group 1: Company Statements and Actions - On June 1, Huaxi Biological issued a statement supporting Dr. Hao Yu in maintaining consumer rights and announced the initiation of a third-party retesting process [2]. - Juzhi Biological responded swiftly, revealing that they had received an apology from the testing agency used by Dr. Hao, claiming that the agency had not authorized him to use the testing report [5]. - Dr. Hao later reported difficulties in contacting the testing agency, leading to a stalemate in the dispute [7][9]. Group 2: Regulatory and Market Reactions - The conflict has drawn regulatory attention, with Huaxi Biological reporting misleading research reports to the China Securities Regulatory Commission [9]. - Huaxi Biological's revenue for 2023 is projected to decline by 4.45% to 6.076 billion yuan, with a significant drop in net profit by 42.44% to 490 million yuan [14]. - Juzhi Biological, on the other hand, has seen substantial growth, with revenue increasing from 2.36 billion yuan in 2022 to 5.539 billion yuan in 2024, reflecting an average annual growth rate of nearly 50% [15]. Group 3: Industry Dynamics and Trends - The article highlights a shift in consumer demand from hyaluronic acid to recombinant collagen, indicating a fundamental change in industry competition [18]. - The cost of producing hyaluronic acid has significantly decreased due to technological advancements, leading to a reduction in profit margins and the erosion of traditional market barriers [18][19]. - New entrants in the market, such as Meiliu Biotechnology, are further driving down costs, potentially disrupting the high-price structure of the recombinant collagen market [19][20].